$4.79 -0.01 (-0.21%)

ENDRA Life Sciences Inc. Common Stock (NDRA)

ENDRA Life Sciences Inc. (NDRA) is a medical technology company focused on developing and commercializing non-invasive imaging solutions. Its platform utilizes ultrasound and thermometry technology to provide innovative imaging options for medical professionals, particularly in the fields of liver health and other disease diagnostics. The company aims to improve patient care through advanced, cost-effective imaging methods.

🚫 ENDRA Life Sciences Inc. Common Stock does not pay dividends

Company News

What 3 Factors Impact Penny Stocks Prices the Most
PennyStocks • J Dylan • June 18, 2024

Here are the 3 factors that impact penny stocks more than others The post What 3 Factors Impact Penny Stocks Prices the Most appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga • Avi Kapoor • April 1, 2024

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Vast Renewables Limited (NASDAQ: VSTE) rose 213.9% to $9.70 in pre-market trading after jumping 39% on Thursday. MediaCo Holding Inc. (NASDAQ: MDIA) gained 84% to $0.9601 in pre-market trading after dipping more than 17% on Thursday. Galera Therapeutics, Inc. (NASDAQ: GRTX) gained 49.5% to $0.2093 in pre-market trading. Galera Therapeutics posted fourth-quarter results on Thursday. Qilian International Holding Group Limited (NASDAQ: QLI) shares gained 32.2% to $0.8399 in pre-market trading. Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 30.7% to $0.0791 in pre-market trading after the company reported operating results for the fiscal year ended Dec. 31, 2023. Xilio Therapeutics, Inc. (NASDAQ: XLO) shares rose 26.8% to $1.37 in pre-market ...

Here's Why ENDRA Life Sciences Inc. (NDRA) Could be Great Choice for a Bottom Fisher
Zacks Investment Research • Zacks Equity Research • December 8, 2022

After losing some value lately, a hammer chart pattern has been formed for ENDRA Life Sciences Inc. (NDRA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.